We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Exagen Inc | NASDAQ:XGN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.015 | 1.08% | 1.40 | 1.35 | 1.75 | 1.42 | 1.3606 | 1.38 | 10,429 | 01:00:00 |
From May 2019 to May 2024
A live audio webcast of the Piper Jaffray presentation will be available online from the investor relations section of the Exagen website at https://investors.exagen.com/ or through the following link:
https://event.webcasts.com/starthere.jsp?ei=1273375&tp_key=2d415e377a
About Exagen Inc.
Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. Exagen has developed and is commercializing a portfolio of innovative testing products under its AVISE® brand, several of which are based on our proprietary Cell-Bound Complement Activation Products, or CB-CAPs, technology. Exagen’s goal is to enable rheumatologists to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including SLE and rheumatoid arthritis.
CONTACTS:
InvestorsWestwicke Partners Mike CavanaughMike.Cavanaugh@westwicke.com646.677.1838 CompanyExagen Inc. Kamal AdawiKAdawi@exagen.com760.477.5514
1 Year Exagen Chart |
1 Month Exagen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
